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A homozygous splicing mutation in ELAC2
suggests phenotypic variability including
intellectual disability with minimal cardiac
involvement
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Abstract
Background: The group of ELAC2-related encephalomyopathies is a recent addition to the rapidly growing
heterogeneous mitochondrial disorders.
Results: We describe a highly inbred consanguineous Pakistani family with multiple affected children in 2 branches
exhibiting moderately severe global developmental delay. Using homozygosity mapping, we mapped the
phenotype in this family to a single locus on chromosome 17. In addition, whole-exome sequencing identified a
homozygous splicing mutation (c.1423 + 2 T > A) in ELAC2 gene that disrupted the canonical donor splice site of
intron 15 of all known isoforms. A noticeable reduction in ELAC2 expression was observed in patients compared to
controls. In addition, patients exhibited significantly increased levels of 5′ end unprocessed mt-RNAs compared to
the control fibroblast cells.
Conclusions: The only three previously reported families with defects in ELAC2 gene exhibited infantile
hypertrophic cardiomyopathy and complex I deficiency. In contrast, our patients exhibited intellectual disability as
the main feature with minimal cardiac involvement. Therefore our findings expand the phenotypic spectrum of
ELAC2- associated disorders illustrating clinical heterogeneity of mutations in this gene. In addition, ELAC2
mutations should be considered when evaluating patient with mainly intellectual disability phenotypes.
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Respiratory chain complex I (RCCI) deficiency
Background
Mitochondria are the key suppliers of cellular-energy
through five protein complexes known as respiratory
chain complexes (RCCI, RCCII, RCCIII, RCCIV, RCCV).
These complexes catalyze the oxidation of nutrients and
the associated energy transduction into ATP via a path-
way known as oxidative phosphorylation. Mitochondrial
disorders refer to a group of extremely heterogeneous
multisystemic clinical presentations. These disorders are
also known as mitochondrial encephalomyopathies since
they are almost always involving the muscle and the
brain, where energy is highly required [1]. Other clinical
manifestations such as blindness, deafness, and move-
ment disabilities may also be present in the spectrum of
the mitochondrial group of disorders. Mitochondrial
encephalomyopathies are mainly caused by mutations
that directly affect the maternally inherited mitochon-
drial DNA (mt-DNA). In addition, a considerable num-
ber of the mitochondrial encephalomyopathies were
found to be associated with mutations in nuclear genes
and hence segregating in autosomal recessive or domin-
ant patterns [1, 2]. The pathogenic mutations in nuclear
genes mostly encode enzymes implicated in the replica-
tion, transcription or translation of the mt-DNA and
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therefore, affecting the biogenesis and maintenance of
the mitochondria [1, 2].
Recently, whole-exome sequencing has been used to un-
ravel the genetic defect underlying a multisystemic mito-
chondorial disorder in three unrelated families [3]. The
phenotype of these patients included infantile hypertrophic
cardiomyopathy, developmental delay, lactic acidosis and
RCCI deficiency (MIM 252010). The authors identified
different compound heterozygous and homozygous patho-
genic mutations in ELAC2 gene (MIM 605367) as the
underlying causes in these families. ELAC2 is a nuclear-
gene located on the short arm of chromosome 17 encoding
Zinc phosphodiesterase ELAC protein 2 (tRNaseZ 2). The
encoded protein has a mitochondrial tRNA 3′-processing
endonuclease activity. It plays a key role in mitochondrial
tRNA maturation by removing a 3′-trailer from precursor
tRNA, a crucial step in tRNA processing [4].
In this paper, we report a large highly inbred Pakistani
family of Baluchi origin with five individuals in two
branches affected by intellectual disability and develop-
mental delay. We mapped the disease-causing gene in
this family to a segment on chromosome 17 and identi-
fied a homozygous splicing mutation in ELAC2 gene. Al-
though previous mutations in this gene were found to
cause hypertrophic cardiomyopathy and complex I defi-
ciency, affected individuals in this report had minimum
cardiac involvement with intellectual disability and de-
velopmental delay being the main presenting features.
Therefore, the clinical and molecular data described in
this manuscript expand the phenotypes associated with
ELAC2 mutations and highlight the clinical heterogen-
eity of ELAC2-related mitochondrial disorders.
Methods
Research subjects
Multiple affected children in two branches of a consan-
guineous family exhibiting severe developmental delay
with very mild hypertrophy of the interventricular septum
have been evaluated (Fig. 1). The study was approved by
Al-Ain District Human Research Ethics Committees
(protocol number 10/09) and the family provided a writ-
ten informed consent for participating in the study.
Genome-wide SNP genotyping and homozygosity
mapping
Genomic DNA was isolated from peripheral blood col-
lected in EDTA tubes from all the family members using
the Flexigene DNA extraction kit (Qiagen, USA). Genotyp-
ing of their whole genome was undertaken using GeneChip
Genome-Wide Human SNP Array 6.0 (Affymetrix, USA).
SNP genotypes were obtained by following the standard
protocols supplied by the manufacturer. Genotypes were
called with the Genotype Console program (Affymetrix,
USA). Generated SNPs derived from the family members’
DNA were loaded into the software package Homozygosi-
tyMapper (http://www.homozygositymapper.org) and sub-
jected to homozygosity mapping analysis [5].
High-throughput sequencing of nuclear and
mitochondrial DNA
Whole-exome sequencing of the extracted nuclear
DNA was performed by Oxford Gene Technology
(Oxfordshire, UK). Nuclear DNA was extracted from
the blood of patients V2 and V10 using Flexigene
DNA extraction kit (Qiagen, USA). Exome capturing
and enrichment was carried out using SureSelect All
Exon V4 kit (Agilent Technologies, USA) following
the manufacturers’ protocols. Whole-exome sequen-
cing was carried out on Illumina HiSeq 2000 system
(Illumina). All the variants were mapped, annotated
and filtered as described previously [5]. Sequencing of
the mt-DNA was carried out as a service by Nijmegen
Centre for Mitochondrial Disorders (NCMD, the
Netherlands). The complete mt-DNA was isolated
from DNA extracted from the skin fibroblasts of pa-
tient V10. The mt-DNA (Genbank accession#
NC_012920.1, 16569 bp) was screened for rearrange-
ments and mismatches using the Ion torrent personal
genome machine (Life Technologies, USA).
Transcript analysis
Total RNA was isolated from fresh blood with QIAamp
RNA blood kit (Qiagen, USA). Single-stranded cDNA was
synthesized from the same starting materials of RNA (1 μg)
using the GoScript reverse transcription system in accord-
ance with the manufacturer’s instructions (Promega, USA).
To avoid genomic amplification, reverse transcription
nested-PCR was carried out with primers spanning the
exon–exon junctions of NM_018127.6. The primers for the
first round PCR F: 5′ TGTGAGAATGCCACCTTTCA 3′
and R: 3′ GCACCAGACAGGTCTGAAACT 5′ generating
product of 967 bp in size. The primer for the second round
nested-PCR NF: 5′ CACCAGTTTCCGCTGTAAGA 3′
and NR: 3′ CAAGGCGCGTTCTCTCTG 5′ generating
product of 499 bp in size. The nested-PCR products were
separated on 2 % agarose gels.
Sanger DNA sequencing
Direct DNA sequencing was carried out using the BigDye
Terminator kit v3.1 (Applied Biosystems, USA). PCR
amplification products were sequenced using the DNA se-
quencing with fluorescent automated sequencing on the
ABI 3130xl genetic analyzer (Applied Biosystems, USA).
Sequencing data were analyzed using ClustalW2 referen-
cing the NM_018127.6 for ELAC2 gene Refseq sequence.
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Fibroblast culturing
Skin biopsy from patient (V10) and normal control were
sliced into smaller pieces and cultured in 6 well plates as
described previously [6].
Quantitative PCR (QPCR) of mt-RNAs of ND1, ND2 and
ATP8 genes
Total RNA was extracted from 1 × 106 cells using
Qiazol reagent (Qiagen, USA) following the manufac-
turer’s instructions. The expression levels of 5′ end
unprocessed mt-RNAs for mtATP8, mtND2, and
mtND4 genes were inspected in fibroblasts from case
1 (V10), and four healthy control samples by means of
qPCR using the QuantStudio® 7 Flex Real-Time PCR
System (Applied Biosystems). Primers used in the
qPCR for mt-RNAs and HPRT1 genes were designed
as described by Haack et al. [3]. Primers bind to the 5′
region for tRNALys (junction ATP8/6), for tRNAArg
(Junction ND4L/ND4), and for tRNALeu(UUR)ND1.
The human HRPT was used as an internal control,
and all experiments were run in quadruplicates and
repeated twice to ensure reproducibility. All reactions
were amplified and quantified in a total volume of
20 μl. The reactions contained 2X SYBR Green PCR
master mix (cat#4309155, Applied Biosystems, USA),
200nM of each primer, and 1 μl of the cDNA samples.
Standard PCR condition was used as follows: 10 min
activation at 95 °C, followed by 40 cycles of amplifica-
tion at 95 °C for 15 s and 60 °C for 1 min. Data ana-
lysis including the threshold cycle (CT) and relative
quantification (RQ) values were calculated using the
QuantStudio® 7 Flex analysis SDS software (Applied
Biosystems, USA).
Western blots
Total protein was extracted from the skin fibroblasts of
patient V10 and two different healthy controls using
radioimmunoprecipitation assay (RIPA) buffer containing
protease and phosphatase inhibitors (Thermo Scientific,
USA). Protein was also extracted from HEK293T cells lys-
ate as an additional control. Protein concentration was de-
termined by the bicinchoninic acid assay (BSA; Sigma,
USA), and ~50ug protein lysates were separated on a 8 %
SDS PAGE and transferred to nitrocellulose membrane.
The blots were blocked in 5 % milk in Phosphate Buffered
Saline with Tween 20 (PBST) and probed with rabbit anti-
ELAC2 antibody (1:100; sc-138774, Santa Cruz, USA)
overnight. Secondary antibody (anti-rabbit; Santa Cruz,
USA) was used at a dilution of (1:5000). The blots were
developed with ECL plus reagent and imaged in Typhoon
FLA 7000 (GE Healthcare Life Sciences, Canada). The
blots were stripped and re-probed with a mouse monoclo-
nal antibody against Tubulin (1:10,000; T5168, Sigma,
USA) which served as a loading control. Densitometric
Fig. 1 Pedigree of the family and key clinical features of patient V10 in this study. a) The main characteristics of autosomal recessive inheritance
including consanguinity and multiple affected children of both sexes can be seen in this pedigree. Circles and squares denote females and males
respectively, filled symbols represent affected members, double lines denote consanguineous marriage. WT: wild-type; Mt: mutant for c.1423 + 2 T > A. b)
a & b, Front and lateral facial photographs of patient V10 showing squint, bulbous nose, low set ears with simple helix and mild micrognathia. c,
Asymmetric buttocks of patient V10 with the right side smaller and the fold is higher than the left. d, T1 saggital view showing cerebellar
hypoplasia. e, T2 axial view showing diffuse increased signal in white matter
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analysis of protein bands was performed using Image Stu-
dio Lite software (LI-COR) and graph was generated using
GraphPad Prism software.
Results
The five affected children in the studied family exhibited
global developmental delay
The affected family is highly inbred Pakistani family of
Baluchi origin (Fig. 1A). The parents of the index case
(V10) are second cousin with two affected children. In
another branch of the family there were three affected
individuals, two girls and a boy.
Case 1 (V10) was a 4 years old boy, the product of nor-
mal pregnancy and delivery. His birth weight was 3 kg
(25th centile). No other measurements were available.
There were no neonatal problems. At the age of 3 months
he had focal left lower limb myoclonic seizure at night
which lasted 2–3 min. He was noted by the parents to
have delayed development at the age of 5 months. He had
no head control and he was unable to roll over. At the age
of 9 months he had seizure-like episodes 3 times with
each of them lasting 1 min. These attacks disappeared and
did not recur. However, he had attacks of head nodding to
the left side several times per day lasting 5 min each. He
was evaluated by us at the age of 3 years because of de-
layed development. At this age he was able to walk hold-
ing furniture and was saying 3–4 words only. On
examination his weight was 11.170 kg (<5th centile), height
82.90 cm (<5th centile), head circumference 45.50 cm
(−4.5 SD). He had left estropia, subtle dysmorphic features
including bulbous nose, thin upper lip, mild micrognathia
and low set ears with simple helix. Deep tendon reflexes
were exaggerated (Fig. 1B-a&b). The fat distribution was
not symmetrical at the buttock area (Fig. 1B-c). The nip-
ples were not inverted. The rest of the examination was
normal. The magnetic resonance imaging (MRI) of the pa-
tient’s brain showed reduced volume of the cerebellar ver-
mis and hemispheres with widening of posterior fossa and
extra-axial cerebrospinal fluid spaces (Fig. 1B-d&e). Dif-
fused abnormal areas of low density bilaterally at the in-
ternal capsule and frontoparietal white matter were also
seen (Fig. 1B-e). Echocardiography showed borderline
hypertrophy of the interventricular septum. The brain
electroencephalogram (EEG) was reported to be normal.
Serum ammonia, amino acid chromatography and urine
organic acids were all normal. Lactic acid was slightly ele-
vated. Transferrin isoelectric focusing was normal. Com-
parative genomic hybridization (CGH) array revealed an
interstitial duplication of 79 oligonucleotide probes from
7q11.3-q21.11 spanning approximately 1.7 MB. The dupli-
cated interval contains approximately 16 known genes.
However, no information regarding a phenotype associ-
ated with duplication of any of these genes is currently
available. Fluorescence in situ hybridization (FISH) testing
of a maternal sample demonstrated that this duplication
was inherited from the mother and was absent in the
other affected siblings indicating that it is a familial variant
without phenotypic significance. Mitochondrial enzymes
(complexes I, II, III, IV, V, pyruvate dehydrogenase, citrate
synthase) measurements in the patient’s (V10) blood and
fibroblast were found to be normal at the age of 5 years.
Case 2 (V11), was the sister of case 1 (V10) . She was
the product of normal pregnancy and delivery. Birth
weight was 2.8 kg (3rd centile). There were no neonatal
problems. She was noted to have developmental delay in
the first few months of life. Evaluation at the age of
2.5 years revealed a weight of 12.94 kg (10 centile),
height 84.2 cm (5th centile), and head circumference of
42.4 cm (−6.5 SD). She had similar subtle dysmorphic
features as her brother. She was unable to walk and had
no speech. Detailed eye examination was normal. Echo-
cardiography revealed some degree of hypertrophy of
the interventricular septum. Array CGH was normal.
Lactic acid was normal.
There were three other affected individuals in another
branch of the same family (Fig. 1A). They were aged
19 years female (V2), 17 years male (V4) and 15 years fe-
male (V5). All had microcephaly and were unable to walk
but can crawl and had 3–4 words sentences. Unfortunately,
they lived in a remote region and we were, therefore, unable
to evaluate them further.
Genome-wide genotyping of the two branches in the
studied family mapped the disease to a single locus on
chromosome 17
To identify the disease locus, whole genome SNP genotyp-
ing was performed for two affected children (V2 and V10),
two parents (IV1 and IV2) and five unaffected siblings (V1,
V3, V6, V8 and V9). Homozygosity mapping analysis of the
generated genotypes revealed a single homozygous region
on chromosome17 (11,496,228–43,871,147) flanked by
rs17514650 and rs12944712 (Fig. 2a). This 32.4 Mb genetic
interval encompassed 796 genes. Using additional genotyp-
ing data from family members, we narrowed down the
interval to 4.37 Mb flanked by rs17514650 and rs17715109.
Next-generation sequencing revealed a splicing
aberration in the nuclear gene ELAC2 while their mtDNA
was normal
In order to reveal the molecular basis of the phenotype in
the studied family, whole-exome sequencing was carried
out on two affected children V2 and V10. A minimum of
72.53 % of the on-target regions was covered to a depth of
at least 20×. Around 88,000 variants from the reference
genome were identified. Of which 11,000 variations were of
serious consequences on the corresponding protein prod-
ucts. After filtering out all the heterozygous reported varia-
tions, around 229 variations were left. Within the mapped
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disease-locus, a splicing mutation (chr17:12,903,471A >T)
was found to be unique and shared between the two af-
fected children (Fig. 2b). The splicing mutation changed a
canonical donor splice site at the 5′ end of intron 15 of
ELAC2 gene. Substituting GT by GA at the splice site be-
tween exon 15 and intron 15 of ELAC2 cDNA
(NM_018127.6:c.1423 + 2 T >A) most probably disrupt its
splicing. This splicing site was found to be shared between
all the known UCSC and RefSeq isoforms of ELAC2 gene
and highly conserved in mammals (Additional file 1: Figure
S1). The aberration was predicted to be disease-causing by
MutationTaster prediction program. This mutation was not
reported in any of the human nuclear genome databases
such as dbSNP, the 1000 Genomes, the NHLBI exome vari-
ant database (http://evs.gs.washington.edu/EVS/), and
ExAC browser (http://exac.broadinstitute.org/). In addition,
it was neither found in the in-house exomes of individuals
exhibiting intellectual disabilities, nor in the GalaxC data-
base (allele frequency database of Arab disease mutations;
https://galaxc.sengenics.com/galaxc/). The segregation of
this mutation was verified using Sanger DNA sequencing
and found to segregate well with the disease in the two
branches of the family of this study (Fig. 2c). Both couples
and all the unaffected individuals were heterozygous for
this mutation. The novelty of the variant was also con-
firmed by its absence in 200 ethnically matched normal
control chromosomes using Sanger sequencing.
To inspect any possible defects in the mitochondrial
genome, the whole mtDNA of patient V10 was sequenced
revealing three rare sequence variations that do not be-
long to the patient’s haplogroup. The m.09067A >G
(p.Met181Val in MT-ATP6) sequence variation is men-
tioned in the human mitochondrial genome databases
MITOMAP’s (0.08 %) and mtDB (0.07 %). This variant is
predicted to be benign by mutation prediction programs
including SIFT and PolyPhen. The m.16207A >G (D-
Loop) sequence variation is mentioned in MITOMAP’s
(0.27 %) and mtDB (0.21 %). The m.16318A > C (DLoop)
sequence variation is mentioned in MITOMAP’s (0.04 %)
and mtDB (0.11 %). Both variants are located in the non-
coding region of the mtDNA.
The c.1423+2T>A mutation in ELAC2 altered its mRNA
splicing pattern and reduced its protein expression
To investigate the consequences of the detected splicing
defect, total RNA was isolated from the leukocytes of
two normal controls (C1 and C2), the mother (VI4) and
the patients (V10 and V11) (Fig. 3a). Amplification of
Fig. 2 Genome-wide genotyping and sequencing results. a) Genome-wide homozygosity mapping analysis revealed one stretch of homozygous
genotypes in all the investigated patients on chromosome17 (indicated by a red bar). b) Whole-exome sequencing IGV of the affected children
V2 and V10 showing a 1 bp substitution of a canonical splice site in all reads of ELAC2 exon 15 . Sequence of wild type gene on reverse strand (-)
and exon annotation at the bottom. c) Sanger sequencing verified that the c.1423 + 2 T > A mutation is homozygous in patients (Patient), hetero-
zygous in parents and some of the unaffected siblings (Carriers) and absent in 100 normal controls (Normal)
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ELAC2 cDNA in all the investigated individuals showed
bright bands at around 499 bp in controls and the
mother, whereas multiple fainter bands were seen in the
patient’s samples (Fig. 3a, lanes 1 & 2). This result sug-
gested a marked reduction in the abundance of the
ELAC2 normal transcript in patients.
Western immune-blotting was used to asses the effect
of the splicing mutation on the expression of the protein
product in the patient’s skin fibroblasts. ELAC2 band of
around 90 KDa was detected in all the investigated con-
trol lysates but not in the patient’s fibroblast (Fig. 3b).
The normalized ELAC2 expression level in patient’s
fibroblast was found to be 14 % of that of the controls’.
The 5′ end unprocessed mt-RNAs in patient’s fibroblasts
are significantly elevated
Quantitative expression of mitochondrial transcripts corre-
sponding to unprocessed ATP8, ND2, and ND4 genes from
case 1 (V10), and four healthy controls were performed
using the QuantStudio® 7 Flex Real-Time PCR. Results
showed significant increase in the levels of expression of
unprocessed mitochondrial transcripts (tRNALys/ATP8,
Fig. 3 Effect of the splicing mutation on ELAC2 expression and on selected mitochondrial genes. a) The amplification products of ELAC2 cDNA
from patients, controls and parents were seen on a 2 % agarose gel. Bright bands were detected in the lanes of two healthy controls (C1 and C2)
and the mother (IV4) at 500 bp (according to the DNA size marker M). Multiple fainter bands were seen in the patients’ (V10 and V11) lanes
suggesting diminished expression of the normal WT transcript and the presence of other abnormal splicing products. b) Expression analysis of
ELAC2 protein in patient fibroblasts. Total protein lysates from patient (V10) and two different control fibroblasts were analyzed for ELAC2 protein
expression by immunoblotting against an antibody specific for ELAC2 isoform1. HEK293T cell lysate was used as a positive control. Mouse Tubulin
antibody was used as a loading control. The levels of the protein was negligible in patient fibroblast compared to the control. Densitometric
analysis of ELAC2 protein bands normalized to Tubulin levels, revealed that ELAC2 protein expression in patient fibroblasts was 14 % of that
detected in control fibroblasts. c) A significant difference is seen between relative expressions of different unprocessed mitochondrial transcripts
mtATP8, mtND2, and mtND4, in skin fibroblasts from patient V10, compared to four different control samples (Ctl1, Ctl2, Ctl5, and Ctl6). The mRNA
expression values were normalized to an internal control HPRT. X axis depicts quantitative expression; Y axis represents bar chart for controls, and
patient samples, respectively
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tRNAArg/ND2, and ND4/tRNALeu(UUR)) in the patient’s sam-
ple (V10) normalized to an internal control HPRT and
compared to healthy control samples (Ctl1, Ctl2, Ctl5, and
Ctl6) (Fig. 3c). For tRNAArg/ND2, the expression levels is
approximately 13 times higher than control samples. More-
over, unprocessed tRNALys/ATP8 and ND4/tRNALeu(UUR)
levels is almost 10 times higher than controls.
Discussion
The human circular double–stranded mitochondorial gen-
ome is transcribed as large polycistronic transcripts from
both strands [1, 7]. These transcripts are then processed to
generate separate 13 messenger (m), 2 ribosomal (r) and
22 transfer (t) RNAs. The mRNAs encode for the RCC
subunits and the rRNAs and tRNAs are required for their
translation. Processing of the precursor transcripts is
achieved via the cleavage of the 5′ and 3′ termini of each
intervening tRNAs, leading to the separation of the adja-
cent mRNAs and rRNAs. The 3′ end processing of the
tRNAs is mainly carried out by the mitochondorial endo-
neoclease tRNaseZ 2 encoded by ELAC2 gene [4, 8].
Mutations in this gene were found to be associated with in-
fantile hypertrophic cardiomyopathy, lactic acidosis and
isolated RCCI deficiency in skeletal muscle in multiple un-
related patients [3]. The authors identified compound het-
erozygous missense (p.T520I) and nonsense (p.R211*)
mutations in two siblings of a non-consanguineous family
(Table 1). In addition, two homozygous missense muta-
tions (p.F154L and p.L423F) were detected in three pa-
tients from two unrelated consanguineous families
(Table 1). Patients’ tissue samples showed accumulation of
unprocessed mt-tRNA intermediates that could be rescued
by expression of wild type ELAC2. The findings were con-
sistent with impaired 3-prime end processing of mt-tRNAs
[3]. Although levels of mature mt-tRNA, mt-mRNA, and
mt-rRNA were normal, patient cells showed increased
levels of unprocessed mt-mRNA and mt-rRNA precursors
and evidence of decreased translation of mitochondrial
proteins. Haack et al. concluded that impaired RNase Z ac-
tivity of ELAC2 causes a fatal failure in cellular energy me-
tabolism by interfering with normal mitochondrial
translation [3].
Table 1 Summary of clinical features of patients with ELAC2 mutations
Families F1 F2 F3 F316
Ethnic German Arabic Turkish Pakistani
Patients #61525 (II-2) #57415 (II-3) #61982 (II-5) #36355 (II-1) #36355 (II-2) V-2 V-4 V-5 V-10a V-11
Sex M M F F F F M F M F
Clinical features
Microcephaly + + ? ? ? ? ? ? + +
Psychomotor
retardation
+ + ? ? ? + + + + +
Muscle
hypotonia
- + + - + ? ? ? + +




Brain MRI NA Hyper-
intensities in
basal ganglia
NA NA Normal at
20 months






































alive at 4 years alive at
2.5 years
mtDNA normal NA NA NA NA NA NA NA normal NA
Zygosity Compound Heterozygous Homozygous Homozygous Homozygous
DNA change c.[631C > T; 1559C > T] c.460 T > C c.1267C > T c.1423 + 2 T > A
Protein
change
p.[Arg211a; Thr520Ile] p.Phe154Leu p.Leu423Phe frameshift
References Haack et al. 2013 [3] This study
HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy, MRI magnetic resonance imaging, Mitoch. mitochondrial. Abbreviations: M male, F female, +
present, - absent, NA not available, a index patient, ? no materiel available
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The main clinical feature in all the reported patients
was severe early-onset hypertrophic cardiomyopathy
(<6 months), whereas developmental delay with varying
degrees of severity was observed in four out of the five
patients (Table 1). Abnormal MRI images, muscular
hypotonia, reduced head control, and delays in motor
development were also common features. Three out of
five died early (6 months, 11 months, 4 years) from car-
diac failure, while two were still alive (2 years, 13 years)
showing constant developmental delay. Lactate levels in
blood were elevated and complex I deficiency was de-
tected in muscles of all the investigated children [3].
In this paper, we present a consanguineous family with
several affected individuals exhibiting severe psycho-
motor developmental delay, muscular hypotonia associ-
ated with subtle dysmorphic facial features. Structural
brain abnormalities were present in the studied patients
(V10 & V11) who had brain imaging. Echocardiography
on the two available affected children (V10 & V11)
showed mild hypertrophy of the inter-ventricular
septum. Mapping the disease in the two branches of this
family revealed a single large homozygous block on
chromosome 17 that is shared by patients but not by the
unaffected family members. Sequencing all the coding-
exons of the nuclear genes in two affected children from
the different branches of the investigated family pointed
out one potential pathogenic mutation (c.1423 + 2 T > A)
in ELAC2. The mutation discovered in the nuclear gene
ELAC2 disrupted a canonical splice donor site and
therefore was predicted to cause a severe damage to the
nascent transcripts. The splicing pattern of ELAC2
mRNA was clearly different and its protein expression
was drastically reduced in patients compared to normal
controls. Mitochondrial enzyme studies were normal.
However, quantification of 5′ unprocessed mt-RNAs
showed significantly increased levels in the patient fibro-
blast sample as compared to healthy controls. This find-
ing confirmed the implication c.1423 + 2 T > A in this
disorder. Unfortunately, parents did not agree to take
muscle biopsy from patient. Moreover, the main feature
in our patients is severe intellectual disability with
asymptomatic minimum septal hypertrophy while the
patients reported by Haack et al. presented with severe
cardiac symptoms due to hypertrophic cardiomyopathy,
which led to death in some of them [3].
Conclusion
In conclusion, the absence of significant cardiomyopathy
and the presence of moderately severe intellectual dis-
ability as the main feature in this family suggest that ab-
errations in ELAC2 should be considered in children
with intellectual disability as the sole presenting feature.
Additional ELAC2 mutations will be helpful for elucidat-
ing the complex relationships between genotypes and
the diverse clinical phenotypes in terms of severity, age
of onset, and spectrum of organ system involvement for
ELAC2-related disorders.
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